Skip to main content
Captor Therapeutics S.A. logo

Captor Therapeutics S.A. — Investor Relations & Filings

Ticker · CTX ISIN · PLCPTRT00014 LEI · 259400JHH1S2I2S4O735 WAR Professional, scientific and technical activities
Open in API
Filings indexed 920 across all filing types
Latest filing 2025-05-27 Interim / Quarterly Rep…
Country PL Poland
Listing WAR CTX

About Captor Therapeutics S.A.

https://www.captortherapeutics.com/

Captor Therapeutics is a biopharmaceutical company focused on the discovery and development of novel therapeutics for diseases with high unmet medical needs. The company specializes in Targeted Protein Degradation (TPD), a technology that enables the elimination of disease-causing proteins previously considered "undruggable." Its core research and development activities are centered on creating new treatments for cancer and autoimmune diseases. To achieve this, Captor Therapeutics utilizes its proprietary Optigrade™ platform. This integrated drug discovery engine combines advanced technologies, including structural biology, proteomics, molecular modeling, and protein engineering, to identify and optimize novel drug candidates. The platform is designed to accelerate the development of degraders with superior therapeutic properties, aiming to provide new treatment options for severe conditions.

Recent filings

Filing Released Lang Actions
Rozszerzony Skonsolidowany Raport kwartalny Grupy Kapitałowej Captor Therapeutics za okres 01.01.2025 r. - 31.03.2025 r.
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Rozszerzony Skonsolidowany Raport kwartalny' (Extended Consolidated Quarterly Report) for the period 01.01.2025 – 31.03.2025. It contains a detailed table of contents covering financial data, management commentary, business activities, and financial analysis. As it is a comprehensive quarterly financial report containing substantive financial data and analysis, it fits the definition of an Interim/Quarterly Report (IR). Q1 2025
2025-05-27 Polish
Zakończenie sporu z Narodowym Centrum Badań i Rozwoju oraz rozwiązanie rezerwy dotyczącej projektu CT-02 - Content (PL)
Legal Proceedings Report Classification · 99% confidence The document text is written in Polish and discusses a decision by the Management Board ('Zarząd') regarding the conclusion of a dispute with the National Centre for Research and Development ('NCBiR'). It details the resolution of a provision ('rezerwę') of 7.9 million PLN, the repayment of funds (4.1 million PLN plus interest), and the resulting recognition of operating income (2.5 million PLN) in Q2 2025 results. This content relates to a significant legal/regulatory matter (a dispute resolution) and its financial impact, but it is not a full financial report (10-K or IR), an earnings release (ER), or a management discussion (MDA). It is a specific update on a legal proceeding and its financial settlement. This fits best under Legal Proceedings Report (LTR) or potentially a general Regulatory Filing (RNS). Given the focus on resolving a dispute and the financial implications, LTR is the most specific fit, as it details the outcome of a significant legal/regulatory matter.
2025-05-27 Polish
Otrzymanie decyzji Narodowego Centrum Badań i Rozwoju w sprawie częściowego zwrotu środków z dofinansowania projektu CT-02 - Content (PL)
Legal Proceedings Report Classification · 99% confidence The document text is written in Polish and discusses a decision received from the National Centre for Research and Development (NCBR) regarding the repayment of project funding. It references previous current reports ('raport bieżący') and details a specific administrative/legal outcome concerning a project (CT-02). This type of communication, detailing significant legal, regulatory, or administrative actions affecting the company's financial standing or operations, fits best under the category of Legal Proceedings Report (LTR) or, given its nature as a mandatory disclosure referencing prior regulatory steps, a general Regulatory Filing (RNS). Since it specifically details the outcome of a dispute/claim from a regulatory body (NCBR) regarding funding repayment, it strongly suggests a legal/regulatory matter update. Given the options, LTR (Legal Proceedings Report) is the most specific fit for reporting on significant legal/administrative disputes, although RNS is a possible fallback. I will classify it as LTR due to the focus on a formal decision regarding repayment/dispute.
2025-05-16 Polish
Rejestracja podwyższenia kapitału zakładowego i zmiany w Statucie Spółki - Content (PL)
Share Issue/Capital Change Classification · 98% confidence The document text, written in Polish, announces that the company's management board registered a change in the company's statute regarding the issuance of 33,138 new ordinary shares (Series U) as part of an incentive program. It details the resulting new structure of the share capital, including the total number of shares and the breakdown by series, and cites Polish financial regulations ('rozporządzenia Ministra Finansów'). This action directly relates to a change in the company's capital structure through the issuance of new shares, which aligns precisely with the definition of 'Share Issue/Capital Change'.
2025-04-29 Polish
Zakończenieumowy o współpracy z Ono Pharmaceutical - Content (PL)
M&A Activity Classification · 99% confidence The document text is very short (919 characters) and announces a specific corporate action: the termination of a cooperation agreement between Captor Therapeutics S.A. and Ono Pharmaceutical Co., Ltd. This is a material event announcement. It does not appear to be a full financial report (10-K, IR), a presentation (IP), or a transcript (CT). It is a specific regulatory disclosure regarding a business relationship change. Since there is no specific category for 'Agreement Termination,' and it is a material, non-financial-result-focused announcement, it fits best under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for miscellaneous corporate disclosures not covered by the more specific codes like DIRS, DIV, or MANG. It is not a proxy statement (PSI), director dealing (DIRS), or capital change (CAP).
2025-04-17 Polish
Raport Biegłego Rewidenta za rok 2024 - podpis
Regulatory Filings Classification · 95% confidence The provided document text consists entirely of XML digital signature blocks (Signatures, SignedInfo, SignatureValue, KeyInfo, X509Data, etc.). This structure is characteristic of a digitally signed document, often used to ensure the integrity and authenticity of an official filing or document. The reference URI points to 'Captor_Therapeutics_SA_2024_BSSF_MSSF_PL.xhtml', suggesting the underlying document is related to financial statements or reports (BSSF/MSSF often relate to financial reporting standards). However, the text provided is *only* the signature wrapper, not the content of the report itself. According to Rule 2, if the document is short and indicates a report is attached or signed, it should be classified as an announcement or wrapper. Since this is the technical signature block of a document, and it doesn't explicitly announce the publication of a report (like an RPA would), the most appropriate general category for a technical, non-content-bearing regulatory artifact that doesn't fit elsewhere is the fallback category, Regulatory Filings (RNS). The document length (5329 chars) is substantial for just a signature block, but the content is purely technical metadata.
2025-04-15 Polish

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.